Clinical Trials Logo

HIV Preexposure Prophylaxis clinical trials

View clinical trials related to HIV Preexposure Prophylaxis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04652700 Completed - Clinical trials for HIV Preexposure Prophylaxis

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Impower-024
Start date: March 15, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with 48 or 96 weeks of treatment and a minimum follow-up of 42 days.

NCT ID: NCT02074891 Completed - Clinical trials for HIV Preexposure Prophylaxis

Sustainable Healthcenter Implementation PrEP Pilot Study

SHIPP
Start date: October 2014
Phase:
Study type: Observational

A health services implementation pilot study, conducted with an observational cohort of HIV-uninfected persons including men who have sex with men, heterosexual women and men, and injection drug users receiving daily oral antiretroviral preexposure prophylaxis (PrEP) at four federally qualified health centers that provide sexual health and primary care services to communities with high HIV incidence/prevalence.